The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2022 | A Phase I/II study evaluating quizartinib plus decitabine and venetoclax in FLT3-mutated AML
Musa Yilmaz, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses a Phase I/II trial investigating the efficacy of the combination of quizartinib plus decitabine and venetoclax in patients with FLT3-mutated acute myeloid leukemia (AML). Dr Yilmaz first provides some background information on the patients enrolled in this trial, and then discusses the response rates and toxicities observed. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Pfizer: Research Funding; Pint Pharma: Honoraria; Daiichi Sankyo: Research Funding
